| P50 | author | Reinhard Dummer | Q32650033 |
| | Phil F Cheng | Q48351688 |
| P2093 | author name string | Michal J Okoniewski | |
| | Hans Steinert | |
| | Maria B Karpova | |
| | Marjam J Barysch | |
| | Mirjana Urosevic-Maiwald | |
| P2860 | cites work | An automated method for finding molecular complexes in large protein interaction networks | Q21284295 |
| | ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks | Q24570122 |
| | The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures | Q27015137 |
| | An immunologic portrait of cancer | Q27028000 |
| | Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. | Q27851723 |
| | Cancer immunoediting: from immunosurveillance to tumor escape | Q28212251 |
| | Interferons, immunity and cancer immunoediting | Q28270336 |
| | Final version of 2009 AJCC melanoma staging and classification | Q29614803 |
| | The immune contexture in human tumours: impact on clinical outcome | Q29620667 |
| | A travel guide to Cytoscape plugins | Q29788355 |
| | An annotation infrastructure for the analysis and interpretation of Affymetrix exon array data | Q31112416 |
| | Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? | Q33205393 |
| | Comprehensive analysis of affymetrix exon arrays using BioConductor | Q33332474 |
| | Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 |
| | Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma | Q33404877 |
| | Normal colon epithelium: a dataset for the analysis of gene expression and alternative splicing events in colon disease | Q33521780 |
| | GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop | Q33711706 |
| | Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib | Q33758211 |
| | A phase II trial of sorafenib in metastatic melanoma with tissue correlates | Q33785790 |
| | PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). | Q33814606 |
| | Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. | Q34231598 |
| | Epidemiology of invasive cutaneous melanoma | Q34610057 |
| | Progress in the management of melanoma in 2013. | Q34737103 |
| | From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 |
| | Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies | Q35212678 |
| | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape | Q35300077 |
| | Interferon-stimulated genes and their antiviral effector functions | Q35742006 |
| | Scaffold mediated regulation of MAPK signaling and cytoskeletal dynamics: a perspective. | Q36445367 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | The MAPK pathway in melanoma | Q37094897 |
| | CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. | Q37279217 |
| | Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. | Q37393627 |
| | Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival | Q37453537 |
| | Gene modulation and immunoregulatory roles of interferon gamma | Q37663048 |
| | Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity | Q37821936 |
| | CXCR3 ligands: redundant, collaborative and antagonistic functions | Q37827339 |
| | Signal control through Raf: in sickness and in health | Q37965017 |
| | The secret ally: immunostimulation by anticancer drugs | Q37981038 |
| | Sorafenib in melanoma | Q37990977 |
| | Update on the current state of melanoma incidence | Q38026612 |
| | Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance | Q38124438 |
| | Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth | Q39284974 |
| | Molecular mechanisms of sorafenib action in liver cancer cells. | Q39313526 |
| | Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. | Q39364248 |
| | Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy | Q39689330 |
| | Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas | Q42397243 |
| | Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering | Q44601660 |
| | Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. | Q46107681 |
| | BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. | Q46460163 |
| | Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 |
| | Host response to human acellular dermal matrix transplantation in a primate model of abdominal wall repair | Q47601354 |
| | Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia | Q47680919 |
| | Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 |
| | Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine. | Q51032411 |
| | Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. | Q54252958 |
| | An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 |
| | Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions | Q58621119 |
| | Changes in serum cytokine concentrations after neurosurgical procedures | Q71724932 |
| | Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy | Q73122441 |
| | Serum imbalance of cytokines in melanoma patients | Q74293420 |
| | Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury | Q82852659 |
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dacarbazine | Q416975 |
| P304 | page(s) | e988458 | |
| P577 | publication date | 2015-01-07 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma | |
| P478 | volume | 4 | |